Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis

Leuk Lymphoma. 2016 Aug;57(8):1945-8. doi: 10.3109/10428194.2015.1115033. Epub 2015 Dec 21.

Authors

Yotaro Ochi¹, Nobuhiro Hiramoto², Yuichiro Ono¹, Satoshi Yoshioka¹, Sumie Tabata¹, Noboru Yonetani¹, Akiko Matsushita¹, Yukihiro Imai³, Takayuki Ishikawa¹

Affiliations

¹ a Department of Hematology , Kobe City Medical Center General Hospital , Kobe , Japan ;
² b Department of Cell Therapy , Institute of Biomedical Research and Innovation , Kobe , Japan ;
³ c Department of Clinical Pathology , Kobe City Medical Center General Hospital , Kobe , Japan.

PMID: 26689650
DOI: 10.3109/10428194.2015.1115033

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Anemia / chemically induced
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Kidney Failure, Chronic / complications
Kidney Failure, Chronic / therapy
Lymphoma, Follicular / complications
Lymphoma, Follicular / drug therapy
Lymphoma, Large B-Cell, Diffuse / complications
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged
Neutropenia / chemically induced
Remission Induction
Renal Dialysis*
Rituximab / administration & dosage
Rituximab / adverse effects
Survival Analysis

Substances

Rituximab